Status:
COMPLETED
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Lead Sponsor:
AstraZeneca
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients wit...
Eligibility Criteria
Inclusion
- Male or female 18 years or older who has been hospitalised for chest pain and potential ACS
- Females of child-bearing potential must have a negative pregnancy test at enrollment and be willing to use 2 methods of reliable contraception
Exclusion
- Persons with moderate or severe liver disease
- Persons who have already been treated with an invasive (angioplasty) procedure for the current episode of ACS
- Persons who are being treated with blood clotting agents that cannot be stopped
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
18624 Patients enrolled
Trial Details
Trial ID
NCT00391872
Start Date
October 1 2006
End Date
March 1 2009
Last Update
March 13 2012
Active Locations (672)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States
2
Research Site
Huntsville, Alabama, United States
3
Research Site
Mobile, Alabama, United States
4
Research Site
Tucson, Arizona, United States